Irbesartan ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing NLRP3 inflammasomes in vivo and in vitro

CONCLUSIONS: Our results suggested that IRB ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing the NLRP3 inflammasomes in vivo and in vitro. These findings provide new therapeutic strategies of diabetic nephropathy.PMID:38503013 | DOI:10.1016/j.intimp.2024.111844

Source: International Immunopharmacology - March 19, 2024 Category: Allergy & Immunology Authors: Yuan Li Weihong Long Haifeng Zhang Meng Zhao Menghan Gao Weiying Guo Lu Yu Source Type: research